Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Streptavidin（SA） Hot |Claudin 18.2 |Cadherin-17 
0
There is no goods in the shopping cart !
My Cart|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF basic

FGF basic

Brief Information

Name:Fibroblast growth factor 2
Target Synonym:FGF-2,Heparin-binding growth factor 2,Basic fibroblast growth factor,FGFB,bFGF,HBGF-2,FGF2,Fibroblast Growth Factor 2 (Basic),Basic Fibroblast Growth Factor BFGF,Prostatropin,Fibroblast Growth Factor 2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
BFF-H5115 Human Human FGF basic (154aa) Protein, premium grade
BFF-H5115-structure
BFF-H5115-sds
FGC-H81E3 Human Biotinylated Human FGF basic Protein, Avitag™,His Tag (MALS verified)
FGC-H81E3-structure
FGC-H81E3-sds
BFF-H4117 Human Human FGF basic Protein, premium grade
BFF-H4117-structure
BFF-H4117-sds
ACRO Quality

Part of Bioactivity data

BFF-H4117-Cell-based assay
FGF basic CELL

Human FGF basic, premium grade (Cat. No. BFF-H4117) stimulates proliferation of NIH/3T3 cells. The specific activity of Human FGF basic, premium grade is >2.5 x 10^6 IU/mg, which is calibrated against human FGF basic WHO International Standard (NIBSC code: 90/712) (QC tested).

Protocol
BFF-H4117-SPR
FGF basic SPR

Immobilized Human FGF basic, premium grade (Cat. No. BFF-H4117) on CM5 Chip can bind Heparin with an affinity constant of 8.37 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol
BFF-H4117-BLI
FGF basic BLI

Loaded Biotinylated Heparin on SA Biosensor, can bind Human FGF basic, premium grade (Cat. No. BFF-H4117) with an affinity constant of 6.27 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

Synonym Name

FGF2,BFGF,FGFB,FGF basic,HBGF-2

Background

FGF basic is a member of the FGF family of at least 23 related mitogenic proteins which show 35-60% amino acid conservation. FGF acidic and basic, unlike the other members of the family, lack signal peptides and are apparently secreted by mechanisms other than the classical protein secretion pathway. FGF basic has been isolated from a number of sources, including neural tissue, pituitary, adrenal cortex, corpus luteum, and placenta. This factor contains four cysteine residues, but reduced FGF basic retains full biological activity, indicating that disulfide bonds are not required for this activity. bFGF is a critical component of human embryonic stem cell culture medium; the growth factor is necessary for the cells to remain in an undifferentiated state, although the mechanisms by which it does this are poorly defined. It has been demonstrated to induce gremlin expression which in turn is known to inhibit the induction of differentiation by bone morphogenetic proteins. It is necessary in mouse-feeder cell dependent culture systems, as well as in feeder and serum-free culture systems.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Thalidomide NSC-66847; NSC-527179; K-17; VP-02 Approved Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Mainland China Leprosy, Lepromatous Fujimoto Pharmaceutical 1982-01-01 Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Muparfostat sodium PI-88 Phase 3 Clinical Australian National University Solid tumours; Liver Neoplasms; Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Fibroblast growth factor 2 gene therapy (ID Pharma) SeV-10101; SEV-10101; DVC-10101; BF-30 Phase 2 Clinical Dnavec Arterial Occlusive Diseases; Intermittent Claudication; Ischemia; Peripheral Arterial Disease Details
RBM-007 RBM-007; ID3 (21); APT-F2 Phase 2 Clinical Ribomic Achondroplasia; Macular Degeneration Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap